Activation of cardiac muscarinic receptor and ischemic preconditioning effects in in situ rat heart.
Activation of cardiac muscarinic receptors by vagal stimulation decreases cardiac work, which may have a protective effect against ischemic injury. To determine whether cardiac muscarinic receptors contribute to the mechanisms of preconditioning effects, we examined the effect of carbachol on ischemia/reperfusion damage and the effect of vagotomy on cardioprotection induced by ischemic preconditioning. Rats were subjected to 30 min of left coronary artery occlusion followed by 30-min reperfusion in situ. Pre-conditioning was induced by three cycles of 2-min coronary artery occlusion and, subsequently by 5 min of reperfusion. The incidence of ischemic arrhythmias, such as ventricular tachycardia (VT) and ventricular fibrillation (VF), and the development of myocardial infarction were markedly reduced by the preconditioning. Carbachol infusion (4 micrograms/kg per min) delayed the occurrence of VT and VF during ischemia and reduced the infarct size. Compared with non-ischemic left ventricle, the cyclic guanosine monophosphate (GMP) content in the ischemic region of the left ventricle was decreased by ischemia/reperfusion, whereas the cyclic adenosine monophosphate (AMP) content of this region was increased. These changes were reversed by preconditioning. Similar changes in cyclic GMP and AMP content in the ischemic region were seen in rats undergoing carbachol treatment. These results suggest the possible contribution of muscarinic receptor stimulation to preconditioning. Vagotomy prior to preconditioning diminished the antiarrhythmic effects, whereas it did not block the anti-infarct effect afforded by pre-conditioning. Vagotomy abolished the preconditioning effect on the tissue cyclic GMP, but it did not attenuate the decrease in tissue cyclic AMP. The results suggest that muscarinic stimulation exerts preconditioning-mimetic protective effects in ischemic/reperfused hearts, but that a contribution of reflective vagal activity to the mechanism for preconditioning is unlikely.
Yamaguchi
F
F
Department of Pharmacology, Tokyo University of Pharmacy and Life Science, Japan.
Nasa
Y
Y
Yabe
K
K
Ohba
S
S
Hashizume
Y
Y
Ohaku
H
H
Furuhama
K
K
Takeo
S
S
D000818:Animals; D001794:Blood Pressure; D002217:Carbachol / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism*; D006321:Heart / Q000187:drug effects / Q000502:physiology*; D006339:Heart Rate; D019157:Ischemic Preconditioning, Myocardial; D008297:Male; D018721:Muscarinic Agonists / Q000494:pharmacology; D017202:Myocardial Ischemia / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011976:Receptors, Muscarinic / Q000502:physiology*; D014628:Vagotomy
D018721:Muscarinic Agonists; D011976:Receptors, Muscarinic; D002217:Carbachol; D000242:Cyclic AMP; D006152:Cyclic GMP